{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T08:02:06Z","timestamp":1725609726411},"publisher-location":"Boston, MA","reference-count":19,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781461371809"},{"type":"electronic","value":"9781461548119"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999]]},"DOI":"10.1007\/978-1-4615-4811-9_34","type":"book-chapter","created":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T18:51:56Z","timestamp":1316112716000},"page":"313-324","source":"Crossref","is-referenced-by-count":4,"title":["Apoptosis by Anthracyclines at Therapeutic Concentrations in MDR1+ Human Leukemic Cells"],"prefix":"10.1007","author":[{"given":"Barbara","family":"Chiodini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Bassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"34_CR1","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.V89.6.1845","volume":"89","author":"YA Hannun","year":"1997","unstructured":"Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845\u20131853, 1997.","journal-title":"Blood"},{"key":"34_CR2","first-page":"2","volume":"16","author":"PAJ Speth","year":"1989","unstructured":"Speth PAJ, Minderman H, Haanen C: Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol 16:2\u20139, 1989 (suppl 2).","journal-title":"Semin Oncol"},{"key":"34_CR3","first-page":"70","volume":"6","author":"MA Ames","year":"1992","unstructured":"Ames MA, Spreafico F: Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 6:70\u201375, 1992 (suppl 1).","journal-title":"Leukemia"},{"issue":"1","key":"34_CR4","first-page":"434a","volume":"86","author":"K Wheatley","year":"1995","unstructured":"Wheatley K: Meta-analysis of randomized trials of idarubicin (IDAR) or mitozantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukemia (AML). Blood 86: 434a, 1995 (suppl 1, abstr).","journal-title":"Blood"},{"key":"34_CR5","first-page":"82","volume":"80","author":"R Bassan","year":"1995","unstructured":"Bassan R, Barbui T: Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age?. Haematologica 80:82\u201390, 1995.","journal-title":"Haematologica"},{"issue":"1","key":"34_CR6","first-page":"257a","volume":"82","author":"D Ross","year":"1993","unstructured":"Ross D, Tong Y, Cornblatt B: Idarubicin (IDA) is less vulnerable to transport-mediated multidrug resistance (MDR) than its metabolite idarubicinol (IDAol) or daunorubicin (DNR). Blood 82: 257a, 1993 (suppl 1, abstr 1015).","journal-title":"Blood"},{"key":"34_CR7","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1182\/blood.V79.12.3267.3267","volume":"79","author":"E Berman","year":"1992","unstructured":"Berman E, McBride M: Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267\u20133273, 1992.","journal-title":"Blood"},{"key":"34_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/978-3-642-71960-8_62","volume-title":"Acute Leukemias VII","author":"B Chiodini","year":"1998","unstructured":"Chiodini B, Bassan R, Borleri G, Lerede T, Barbui T. Idarubicin activity against multidrug resistant (mdr-1+) cells is increased by cyclosporin A. In: Hiddemann W et al (eds.) Acute Leukemias VII. Springer, Berlin 1998, pp. 475\u2013482."},{"key":"34_CR9","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood.V86.6.2329.bloodjournal8662329","volume":"86","author":"CP Leith","year":"1995","unstructured":"Leith CP, Chen I-M, Kopecky KJ, et al: Correlation of multidrug resistance (MDR1) protein expression with functional dye\/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-\/efflux+ and MDR+\/efflux- cases. Blood 86:2329\u20132342, 1995.","journal-title":"Blood"},{"key":"34_CR10","first-page":"6525","volume":"50","author":"JM Reid","year":"1990","unstructured":"Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM: Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients. A Childrens Cancer Study Group report. Cancer Res 50:6525\u20136528, 1990.","journal-title":"Cancer Res"},{"key":"34_CR11","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.1993.11.9.1652","volume":"11","author":"AF List","year":"1993","unstructured":"List AF, Speier C, Greer J, et al: Phase I\/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652\u20131660, 1993.","journal-title":"J Clin Oncol"},{"key":"34_CR12","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood.V84.5.1415.bloodjournal8451415","volume":"84","author":"G Koopman","year":"1994","unstructured":"Koopman G, Reutelingsperger CPM, Kuijten GAM, et al: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415\u20131420, 1994.","journal-title":"Blood"},{"key":"34_CR13","first-page":"511","volume":"2","author":"E Kokenberg","year":"1988","unstructured":"Kokenberg E, Sonneveld P, Delwel R, et al: In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia 2:511\u2013517, 1988.","journal-title":"Leukemia"},{"issue":"2","key":"34_CR14","first-page":"S46","volume":"10","author":"AF List","year":"1996","unstructured":"List AF: The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 10: S46\u2013S51, 1996 (suppl 2).","journal-title":"Leukemia"},{"key":"34_CR15","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1200\/JCO.1992.10.11.1730","volume":"10","author":"E Solary","year":"1992","unstructured":"Solary E, Caillot D, Chauffert B, et al: Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730\u20131736, 1992.","journal-title":"J Clin Oncol"},{"key":"34_CR16","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1997.15.5.1796","volume":"15","author":"SM Kornblau","year":"1997","unstructured":"Kornblau SM, Estey E, Madden T, et al: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15:1796\u20131802, 1997.","journal-title":"J Clin Oncol"},{"key":"34_CR17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.V91.3.1001","volume":"91","author":"C Ito","year":"1998","unstructured":"Ito C, Ribeiro RC, Behm FG, Raimondi SC, Pui C-H, Campana C. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood 91:1001\u20131007, 1998.","journal-title":"Blood"},{"key":"34_CR18","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.V83.5.1337.1337","volume":"83","author":"DD Ross","year":"1994","unstructured":"Ross DD, Wooten PJ, Tong Y, et al: Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia by cyclosporin A and cremophor EL. Blood 83:1337\u20131347, 1994.","journal-title":"Blood"},{"issue":"1","key":"34_CR19","first-page":"786a","volume":"86","author":"M Weiss","year":"1995","unstructured":"Weiss M, Maslak P, Megherian L, Scheinberg D. A phase I trial of a single high dose of idarubicin combined with high dose cytarabine (ARA-C) as induction therapy in relapsed and refractory adult patients with acute lymphoblastic leukemia (ALL). Blood 86: 786a, 1995 (suppl 1, abstr 3131).","journal-title":"Blood"}],"container-title":["Advances in Experimental Medicine and Biology","Drug Resistance in Leukemia and Lymphoma III"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4615-4811-9_34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T23:45:53Z","timestamp":1592955953000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4615-4811-9_34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999]]},"ISBN":["9781461371809","9781461548119"],"references-count":19,"URL":"https:\/\/doi.org\/10.1007\/978-1-4615-4811-9_34","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[1999]]}}}